Related Experiment Video
Updated: Oct 18, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes
Motonori Sato1, Yoshifumi Tamura1,2, Hideyoshi Kaga1
1Department of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Biomedicines
|September 28, 2021
Summary
Tofogliflozin did not alter insulin clearance in men with type 2 diabetes. This suggests that improved glycemic control with SGLT2 inhibitors does not rely on increased metabolic clearance rate of insulin.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Decreased insulin clearance is linked to obesity, metabolic syndrome, and NAFLD.
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) may improve insulin clearance.
- Tofogliflozin is an SGLT2i with potential metabolic benefits.
Purpose of the Study:
- To evaluate the effect of tofogliflozin on the metabolic clearance rate of insulin (MCRI).
- To assess changes in tissue-specific insulin sensitivity and ectopic fat.
- To determine if tofogliflozin impacts systemic insulin clearance.
Main Methods:
- Hyperinsulinemic euglycemic clamp study in 12 Japanese men with type 2 diabetes.
- MCRI and insulin sensitivity measured before and after single-dose and 8-week tofogliflozin treatment.
- Ectopic fat and abdominal fat area assessed using MRI and MRS.
Main Results:
- Tofogliflozin did not significantly change MCRI after single dose or 8 weeks.
- Significant improvements in HbA1c, body weight, and subcutaneous fat area observed after 8 weeks.
- No significant changes in insulin sensitivity or ectopic fat content.
Conclusions:
- Tofogliflozin does not acutely or chronically increase MCRI.
- Increased MCRI is not a prerequisite for the beneficial effects of tofogliflozin on body fat or glycemic control.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
308
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
308
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
346
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
346
01:23Dipeptidyl Peptidase 4 Inhibitors
293
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
293
01:16Insulin: Dosing Regimen and Adverse Effects
307
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
307
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
320
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
320
01:24Glucagon-like Receptor Agonists
480
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
480